Want to see TSE:BU full AI Analyst Report?
BU Stock Chart & Stats
C$1.70
C$0.25(14.71%)
At close: 4:00 PM EDT
C$1.70
C$0.25(14.71%)
Day’s Range― - ―
52-Week RangeC$1.51 - C$2.75
Previous CloseN/A
Volume4.94K
Average Volume (3M)6.58K
Market Cap
C$21.58M
Enterprise ValueC$52.20
Total Cash (Recent Filing)C$866.46K
Total Debt (Recent Filing)C$28.95M
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Nov 18, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.14
Shares Outstanding12,692,942
10 Day Avg. Volume9,144
30 Day Avg. Volume6,578
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)-4.05
Price to Sales (P/S)10.37
P/FCF Ratio-2.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.09
Revenue Forecast (FY)C$11.60M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Customer AdoptionStrong sequential growth combined with repeat purchases indicates improving product-market fit and customer adoption. If sustained, this can build a more recurring revenue base and support operating leverage as commercial volumes expand.
Scalable Product PortfolioCommercial production across several plant-protein sources demonstrates that Burcon’s technology can address multiple applications and raw materials. Broader product coverage may diversify revenue opportunities and strengthen partner adoption over time.
Proprietary Plant-Protein TechnologyPatented extraction and purification processes provide an intellectual-property foundation for licensing, royalties and strategic partnerships. An asset-light commercialization model could allow participation in industry growth without funding all manufacturing internally.
Bears Say
Deep Losses And Persistent Cash BurnSevere negative margins and ongoing operating cash outflows show that revenue growth has not yet produced a viable economic model. Continued losses may require further capital and could delay the company’s transition to self-funded expansion.
High Leverage And Negative EquityNegative equity and debt exceeding the asset base materially reduce financial flexibility. The pressured capital structure increases refinancing and solvency risk, while interest and debt obligations may constrain investment in production and commercialization.
Capacity And Commercial Execution RiskProduction limitations could prevent Burcon from converting customer interest into revenue, even where demand exists. Reliance on a manufacturing partner and required capacity investments create timing, execution and supply-availability risks during the growth phase.
Burcon Nutrascience News
BU FAQ
What was Burcon Nutrascience’s price range in the past 12 months?
Burcon Nutrascience lowest stock price was C$1.51 and its highest was C$2.75 in the past 12 months.
What is Burcon Nutrascience’s market cap?
Burcon Nutrascience’s market cap is C$21.58M.
When is Burcon Nutrascience’s upcoming earnings report date?
Burcon Nutrascience’s upcoming earnings report date is Nov 18, 2026 which is in 86 days.
How were Burcon Nutrascience’s earnings last quarter?
Burcon Nutrascience released its earnings results on Aug 12, 2026. The company reported -C$0.3 earnings per share for the quarter, missing the consensus estimate of -C$0.07 by -C$0.23.
Is Burcon Nutrascience overvalued?
According to Wall Street analysts Burcon Nutrascience’s price is currently Overvalued.
Does Burcon Nutrascience pay dividends?
Burcon Nutrascience does not currently pay dividends.
What is Burcon Nutrascience’s EPS estimate?
Burcon Nutrascience’s EPS estimate is -0.17.
How many shares outstanding does Burcon Nutrascience have?
Burcon Nutrascience has 12,692,942 shares outstanding.
What happened to Burcon Nutrascience’s price movement after its last earnings report?
Burcon Nutrascience reported an EPS of -C$0.3 in its last earnings report, missing expectations of -C$0.07. Following the earnings report the stock price went up 0.813%.
Which hedge fund is a major shareholder of Burcon Nutrascience?
Currently, no hedge funds are holding shares in TSE:BU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Burcon Nutrascience
Burcon NutraScience Corporation, along with its associated entities, is a Canadian enterprise specializing in the development and commercialization of plant-derived proteins and functional ingredients for the food and beverage sectors. Its extensive product line features Peazazz, a versatile pea protein suitable for a range of applications including dairy alternatives, ready-to-drink and dry-blended beverages, snack bars, baked goods, and meat substitutes. Also derived from peas, Peazac and Peazac 850 are tailored for plant-based meat alternatives, ready-to-mix powders and drinks, dairy-free options, and nutritional bars, particularly valued for their neutral taste profile and moderate textural properties. Among its canola-based proteins is Puratein, an isolate frequently utilized in meat alternatives such as burgers and sausages, as well as nutrition bars. Supertein, a pale-hued canola protein powder, is incorporated into non-dairy frozen desserts, egg replacers, plant-based marshmallows, ready-to-mix beverages, whipped toppings, and plant-based snack bars. Additionally, Nutratein, a canola protein composed of globulin and albumin, finds utility in meat and egg alternatives, alongside various other functional plant-based foods. Further expanding its offerings are Nutratein-PS and Nutratein-TZ, custom blends featuring its Peazac pea protein, alongside CLARISOY, a soy protein employed across sports nutrition beverages, citrus and fruit-flavored drinks, lemonades, powdered beverage mixes, and diverse other food and dietary items. Finally, MeritPro stands as a unique nutritional protein blend, distinguished by being allergen-free, gluten-free, dairy-free, non-GMO, and vegan-friendly. Originally incorporated in 1998 as Burcon Capital Corp., the firm rebranded to Burcon NutraScience Corporation in October 1999. Its corporate headquarters are situated in Vancouver, Canada.
BU Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was constructive and execution-focused: management reported strong sequential and year-over-year revenue growth (54% QoQ; >3x YoY), growing customer adoption with 40 active buyers and repeat purchases, production scaling across multiple products, and put in place financing (up to $8.1M convertible debentures plus $3M undrawn tranche) to expand capacity and pursue near-term targets. Material risks remain — the company is still unprofitable, depends on additional funding and capacity expansions, and growth is back-end loaded and contingent on converting its sales funnel. On balance, the positives around commercial validation, production progress and committed financing outweigh the risks, although execution and timing remain key.View all TSE:BU earnings summaries




